Following induction, the patient achieved morphologic complete remission (CR) of his AML; however, low-level residual disease was identified by cytogenetics (3 of 20 cells with the prior abnormal clone) and massively parallel sequencing analysis (1 % TP53 and 2 % NRAS mutant allele frequencies). Here, TP53 is linked to acute myeloid leukemia.